X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · Real-Time Price · USD

3.980

-0.020 (-0.50%)

At close: Jul 31, 2026, 4:00 PM EDT

3.970

-0.010 (-0.25%)

After-hours: Jul 31, 2026, 7:34 PM EDT

X4 Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	216.91	217.05	55.7	99.22	121.72	81.79
Short-Term Investments	16.81	35.95	46.36	15	-	-
Cash & Short-Term Investments	233.72	253	102.06	114.22	121.72	81.79
Cash Growth	168.80%	147.89%	-10.64%	-6.16%	48.82%	3.91%
Accounts Receivable	1.11	0.57	1.07	-	-	-
Other Receivables	-	-	0.64	0.56	1.15	0.75
Total Trade Receivables	1.11	0.57	1.71	0.56	1.15	0.75
Inventory	4.64	4.48	2.82	-	-	-
Other Current Assets	2.51	3.53	5.59	7.3	5.81	5.34
Total Current Assets	241.98	261.58	112.18	122.08	128.68	87.88
Net Property, Plant & Equipment	1.18	1.59	4.84	6.4	8.33	10.22
Other Intangible Assets	9.06	9.25	10	-	-	-
Goodwill	17.35	17.35	17.35	17.35	17.35	17.35
Other Long-Term Assets	0.7	0.69	2.08	1.44	1.23	1.72
Total Assets	270.28	290.46	146.45	147.26	155.59	117.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.07	5.7	8.62	8.95	7.78	4.28
Accrued Expenses	17.06	18.6	23.01	12.82	12.03	7.87
Current Portion of Long-Term Debt	-	-	-	-	1.32	0.8
Current Portion of Leases	0.73	0.99	1.25	1.1	1.2	1.08
Unearned Revenue	0.91	0.46	-	-	-	-
Total Current Liabilities	23.77	25.76	32.88	22.86	22.32	14.02
Long-Term Debt	76.52	76.29	75.43	54.57	32.3	33.14
Long-Term Leases	-	-	1.41	2.61	3.6	4.78
Other Long-Term Liabilities	1.54	2.12	14.59	16.12	23.3	0.83
Total Long-Term Liabilities	78.06	78.41	91.42	73.3	59.21	38.74
Total Liabilities	101.83	104.17	124.3	96.16	81.54	52.76

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.09	0.09	0.01	0.17	0	0.03
Additional Paid-in Capital	783.27	780.86	537.62	528.96	450.79	347.37
Accumulated Other Comprehensive Income	-0.12	-0.11	-0.12	-0.12	-0.12	-0.12
Retained Earnings	-614.8	-594.55	-515.36	-477.91	-376.74	-282.87
Shareholders' Equity	168.45	186.29	22.15	51.1	73.93	64.41
Total Liabilities & Equity	270.28	290.46	146.45	147.26	155.59	117.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	77.25	77.29	78.09	58.28	38.42	39.79
Net Cash (Debt)	156.47	175.71	23.97	55.94	83.3	42
Net Cash Growth	1656.08%	632.93%	-57.14%	-32.85%	98.32%	4.33%
Net Cash Per Share	2.17	4.16	3.58	9.44	39.34	48.94
Book Value	168.45	186.29	22.15	51.1	73.93	64.41
Book Value Per Share	2.34	4.40	3.30	8.62	34.91	75.05
Tangible Book Value	142.04	159.69	-5.2	33.75	56.58	47.06
Tangible Book Value Per Share	1.97	3.78	-0.78	5.69	26.72	54.83

SEC Filings: 10-K · 10-Q